毕得医药股价涨5.1%，国都证券旗下1只基金重仓，持有7000股浮盈赚取2.52万元

Core Viewpoint - Bid Pharma's stock increased by 5.1% to 74.18 CNY per share, with a total market capitalization of 6.742 billion CNY as of September 24 [1] Company Overview - Shanghai Bid Pharma Technology Co., Ltd. was established on April 27, 2007, and listed on October 11, 2022 [1] - The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - Main business revenue composition: - Heterocyclic compounds: 43.26% - Aromatic compounds: 23.32% - Aliphatic compounds: 16.36% - Catalysts and ligands: 10.57% - Life science reagents: 6.49% [1] Fund Holdings - Guodu Securities has a fund that heavily invests in Bid Pharma, with Guodu Jucheng (011389) holding 7,000 shares, representing 3.98% of the fund's net value [2] - The fund has generated a floating profit of approximately 25,200 CNY as of the report date [2] Fund Manager Performance - Guodu Jucheng (011389) has three fund managers: - Liao Xiaodong: 5 years and 134 days of tenure, with a best return of -24.14% and worst return of -63.61% [3] - Zhang Xiaolei: 6 years and 284 days of tenure, with a best return of 80.09% and worst return of -23.54% [3] - Gong Yongjin: 1 year and 175 days of tenure, with a consistent return of 7.81% [3]